UiPath (NYSE:PATH) Trading Down 2.8%

UiPath Inc. (NYSE:PATH)’s share price dropped 2.8% during mid-day trading on Monday . The company traded as low as $20.07 and last traded at $20.12. Approximately 3,313,244 shares were traded during trading, a decline of 63% from the average daily volume of 8,982,307 shares. The stock had previously closed at $20.71.

Analyst Upgrades and Downgrades

PATH has been the topic of a number of research analyst reports. DA Davidson increased their price target on UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, March 14th. Wells Fargo & Company increased their price target on UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a report on Thursday, March 14th. Evercore ISI increased their price target on UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a report on Thursday, March 14th. William Blair started coverage on UiPath in a report on Tuesday, January 2nd. They issued an “outperform” rating on the stock. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $29.00 target price on shares of UiPath in a report on Monday, April 1st. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.41.

UiPath Price Performance

The business has a 50-day moving average of $23.16 and a 200 day moving average of $21.47.

UiPath (NYSE:PATH) last released its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million during the quarter, compared to analyst estimates of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. As a group, equities analysts anticipate that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the sale, the chief financial officer now directly owns 103,505 shares of the company’s stock, valued at approximately $2,325,757.35. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold a total of 72,000 shares of company stock valued at $1,591,360 in the last ninety days. 31.03% of the stock is currently owned by insiders.

Institutional Investors Weigh In On UiPath

Several large investors have recently made changes to their positions in the business. Intech Investment Management LLC increased its position in shares of UiPath by 3.1% during the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after purchasing an additional 426 shares during the last quarter. 180 Wealth Advisors LLC increased its holdings in UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after acquiring an additional 492 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in UiPath by 4.9% in the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after acquiring an additional 598 shares during the last quarter. Simplicity Solutions LLC increased its holdings in UiPath by 4.9% in the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after acquiring an additional 598 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in UiPath by 40.2% in the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after acquiring an additional 632 shares during the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.